Review of gemcitabine in biliary tract carcinoma.
暂无分享,去创建一个
[1] D. D. Hoff,et al. Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabine , 2004, Investigational New Drugs.
[2] J. Hainsworth,et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] P. Hammel,et al. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] G. Colucci,et al. Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] N. Bundred,et al. Predicting sentinel node involvement: Manchester experince , 2001 .
[6] I. Vlachonikolis,et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial , 2001, The Lancet.
[7] C. Tournigand,et al. A phase II study of gemcitabine and oxaliplatin (gemox) in advanced biliary adenocarcinoma (ABA). Preliminary results , 2001 .
[8] W. Scheithauer,et al. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] Taylor Murray,et al. Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.
[10] T. Lehnert,et al. Chemotherapy with gemcitabine in patients with advanced gallbladder carcinoma. , 2000, Zeitschrift fur Gastroenterologie.
[11] F. Verderame,et al. Biliary tract cancer: our experience with gemcitabine treatment. , 2000, Anti-cancer drugs.
[12] M. Dintinjana,et al. Gemcitabine in patients with nonresectable cancer of the biliary system or advanced gallbladder cancer , 2000, American Journal of Gastroenterology.
[13] M. Dintinjana,et al. Improvement in survival and clinical benefit response for patients with metastatic pancreatic cancer , 2000, American Journal of Gastroenterology.
[14] W. Scheithauer,et al. A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma , 2000, Cancer.
[15] H. Kantarjian,et al. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] W. Scheithauer,et al. Gemcitabine for the Treatment of Advanced Biliary Tract Carcinomas: Evaluation of Two Different Dose Regimens , 1999, Oncology Research and Treatment.
[17] M. Manns,et al. Phase II study of gemcitabine in patients with nonresectable cancer of the biliary system , 1999 .
[18] G. Gores,et al. Biliary tract cancers. , 1999, The New England journal of medicine.
[19] W. Scheithauer,et al. [In vitro evaluation of potentially effective gemcitabine combination therapy for exocrine pancreatic carcinoma]. , 1999, Acta medica Austriaca.
[20] E. Raymond,et al. Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines , 1999, Cancer Chemotherapy and Pharmacology.
[21] J. Gallardo,et al. Efficacy of gemcitabine in the treatment of patients with gallbladder carcinoma , 1998, Cancer.
[22] T. Sauerbruch,et al. Phase II Study with Gemcitabine in Gallbladder and Biliary Tract Carcinomasa , 1998, Oncology Research and Treatment.
[23] M. Pruckmayer,et al. The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature. , 1998, European journal of cancer.
[24] M. Castro. Efficacy of gemcitabine in the treatment of patients with gallbladder carcinoma , 1998, Cancer.
[25] D. V. Von Hoff,et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] L. Crinò,et al. Combination therapy with gemcitabine in non-small cell lung cancer. , 1997, European journal of cancer.
[27] S. Lippman,et al. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] R. Larsson,et al. Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors. , 1995, Seminars in oncology.
[29] G. Peters,et al. Interaction between cisplatin and gemcitabine in vitro and in vivo. , 1995, Seminars in oncology.
[30] G. Peters,et al. Introduction: Gemcitabine - Status of preclinical studies and perspectives for future clinical applications of this novel nucleoside analog , 1995 .
[31] Y Z Xu,et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine. , 1990, Molecular pharmacology.